Journal
NEUROBIOLOGY OF STRESS
Volume 11, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ynstr.2019.100196
Keywords
Allopregnanolone; Brexanolone; SGE-217; Steroid enantiomers; Tonic inhibition
Categories
Funding
- Taylor Family Institute for Innovative Psychiatric Research
- Bantly Foundation
- Sage Therapeutics
- [MH101874]
- [MH114866]
- [MH110550]
- [AA026753]
Ask authors/readers for more resources
The recent FDA approval of the neurosteroid, brexanolone (allopregnanolone), as a treatment for women with postpartum depression, and successful trials of a related neuroactive steroid, SGE-217, for men and women with major depressive disorder offer the hope of a new era in treating mood and anxiety disorders based on the potential of neurosteroids as modulators of brain function. This review considers potential mechanisms contributing to antidepressant and anxiolytic effects of allopregnanolone and other GABAergic neurosteroids focusing on their actions as positive allosteric modulators of GABA(A) receptors. We also consider their roles as endogenous stress modulators and possible additional mechanisms contributing to their therapeutic effects. We argue that further understanding of the molecular, cellular, network and psychiatric effects of neurosteroids offers the hope of further advances in the treatment of mood and anxiety disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available